Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma - GlioVax
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
At a glance
- Drugs GlioVax (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms GlioVax
- 08 May 2018 Planned End Date changed from 6 Apr 2023 to 6 Jun 2023.
- 08 May 2018 Planned primary completion date changed from 6 Jul 2022 to 6 Sep 2022.
- 08 May 2018 Status changed from not yet recruiting to recruiting.